---
title: "TAK.US (TAK.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/TAK.US/news.md"
symbol: "TAK.US"
name: "TAK.US"
parent: "https://longbridge.com/en/quote/TAK.US.md"
datetime: "2026-03-07T07:58:04.641Z"
locales:
  - [en](https://longbridge.com/en/quote/TAK.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/TAK.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/TAK.US/news.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/TAK.US/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/TAK.US/news.md)


# TAK.US (TAK.US) — Related News

### [H. pylori Infections Market in the 6MM to Observe Stupendous Growth at a CAGR of 9.5% During the Forecast Period (2026-2036) | DelveInsight | CPIX Stock News](https://longbridge.com/en/news/277844408.md)
*2026-03-04T14:46:00.000Z*
> The H. pylori infections market is projected to grow at a CAGR of 9.5% from 2026 to 2036, driven by advancements in trea

### [Takeda Pharmaceutical to Cut 400 US Jobs, Invest in Blood Products](https://longbridge.com/en/news/277827484.md)
*2026-03-04T20:08:17.000Z*
> Takeda Pharmaceutical to Cut 400 US Jobs, Invest in Blood Products

### [What Takeda Pharmaceutical (TSE:4502)'s Pediatric ENTYVIO Phase 3 Success Means For Shareholders](https://longbridge.com/en/news/277484447.md)
*2026-03-02T14:36:48.000Z*
> Takeda Pharmaceutical announced positive Phase 3 KEPLER trial results for ENTYVIO, showing effectiveness in treating ped

### [Takeda, Protagonist Say FDA Accepts New Drug Application for Potential Polycythemia Vera Treatment](https://longbridge.com/en/news/277429641.md)
*2026-03-02T08:31:06.000Z*
> Takeda, Protagonist Say FDA Accepts New Drug Application for Potential Polycythemia Vera Treatment

### [](https://longbridge.com/en/news/277417532.md)
*2026-03-02T07:03:10.000Z*
> Takeda Pharmaceutical Company: Takeda announced that the U.S. Food and Drug Administration has accepted the new drug app

### [Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera | TAK Stock News](https://longbridge.com/en/news/277420364.md)
*2026-03-01T23:00:00.000Z*
> Takeda and Protagonist Therapeutics announced that the U.S. FDA has accepted the New Drug Application for rusfertide, gr

### [Baorui Zhongli Factory upgraded to a bonded factory, key customer North America renews contract, CDMO export momentum further enhanced](https://longbridge.com/en/news/276576067.md)
*2026-02-23T08:05:59.000Z*
> Boryung (6472) announced that its Zhongli plant has been approved to upgrade to a bonded factory, enhancing CDMO export